Corrections.
Bourlière M, Bronowicki J-P, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397–404—In the second paragraph of the Randomisation and Masking section the sentence describing study drug assignment should have read: “Patients were assigned in a 1:1 ratio. In the ledipasvir-sofosbuvir plus ribavirin group..." [see text]